{"sentence": "<e1> Moxifloxacin </e1> and Lomefloxacin reacts faster with <e2> sucralfate </e2> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.", "relation": "1", "e1": "Moxifloxacin", "e2": "sucralfate", "evs": ""}
{"sentence": "Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e2> antipyrine </e2> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.", "relation": "0", "e1": "pantoprazole", "e2": "antipyrine", "evs": ""}
{"sentence": "These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e1> hypoglycemics </e1> : Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;", "relation": "0", "e1": "hypoglycemics", "e2": "DIFLUCAN", "evs": ""}
{"sentence": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and <e1> clarithromycin </e1> ), may alter <e2> oxybutynin </e2> mean pharmacokinetic parameters (i.e., Cmax and AUC).", "relation": "1", "e1": "clarithromycin", "e2": "oxybutynin", "evs": ""}
{"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).", "relation": "0", "e1": "Asendin", "e2": "Norpramin", "evs": ""}
{"sentence": "Addition of <e1> mexiletine </e1> to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than <e2> propafenone </e2> alone.", "relation": "0", "e1": "mexiletine", "e2": "propafenone", "evs": ""}
{"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1> neuroleptics </e1> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .", "relation": "1", "e1": "neuroleptics", "e2": "MIRAPEX", "evs": ""}
{"sentence": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids.", "relation": "1", "e1": "Salicylate", "e2": "naproxen", "evs": ""}
{"sentence": "The preclinical combination of <e1> lenalidomide </e1> with the mTOR inhibitor <e2> CCI-779 </e2> has displayed synergy in vitro and represents a novel combination in MM.", "relation": "1", "e1": "lenalidomide", "e2": "CCI-779", "evs": ""}
{"sentence": "A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> MYCAMINE </e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and <e2> rifampin </e2> .", "relation": "0", "e1": "MYCAMINE", "e2": "rifampin", "evs": ""}
{"sentence": "In female rats, neonatal quinpirole treatment enhanced <e1> amphetamine </e1> locomotor sensitization compared with <e2> quinpirole </e2> -free controls sensitized to amphetamine.", "relation": "0", "e1": "amphetamine", "e2": "quinpirole", "evs": ""}
{"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> metformin </e1> , cimetidine, <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine.", "relation": "0", "e1": "metformin", "e2": "ranitidine", "evs": ""}
{"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .", "relation": "1", "e1": "dopamine antagonists", "e2": "MIRAPEX", "evs": ""}
{"sentence": "ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and doxazosin, can antagonize the effects of <e2> ProAmatine </e2> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.", "relation": "1", "e1": "terazosin", "e2": "ProAmatine", "evs": ""}
{"sentence": "Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1> terfenadine </e1> , <e2> astemizole </e2> , cisapride, cyclosporine, and tricyclic antidepressants.", "relation": "0", "e1": "terfenadine", "e2": "astemizole", "evs": ""}
{"sentence": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1> reverse transcriptase inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).", "relation": "0", "e1": "reverse transcriptase inhibitors", "e2": "ketoconazole", "evs": ""}
{"sentence": "In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with <e2> dornase alfa </e2> (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.", "relation": "1", "e1": "TOBI", "e2": "dornase alfa", "evs": ""}
{"sentence": "Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of <e1> curariform drugs </e1> (such as <e2> tubocurarine </e2> ) the most serious effect would be respiratory depression which could proceed to apnea.", "relation": "0", "e1": "curariform drugs", "e2": "tubocurarine", "evs": ""}
{"sentence": "The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1> pseudoephedrine </e1> , ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of <e2> ProAmatine </e2> . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.", "relation": "1", "e1": "pseudoephedrine", "e2": "ProAmatine", "evs": ""}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1> clindamycin </e1> , <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "relation": "0", "e1": "clindamycin", "e2": "colistin", "evs": ""}
{"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "relation": "0", "e1": "isocarboxazid", "e2": "potassium chloride", "evs": ""}
{"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and <e1> rifampin </e1> may increase the clearance of corticosteroids and may require increases in <e2> corticosteroid </e2> dose to achieve the desired response.", "relation": "1", "e1": "rifampin", "e2": "corticosteroid", "evs": ""}
{"sentence": "The bioavailability of <e1> SKELID </e1> is decreased 80% by <e2> calcium </e2> , when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.", "relation": "1", "e1": "SKELID", "e2": "calcium", "evs": ""}
{"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that <e1> NSAIDs </e1> can reduce the natriuretic effect of furosemide and <e2> thiazide diuretics </e2> in some patients.", "relation": "1", "e1": "NSAIDs", "e2": "thiazide diuretics", "evs": ""}
{"sentence": "There is usually complete cross-resistance between <e1> PURINETHOL </e1> (mercaptopurine) and <e2> TABLOID </e2> brand Thioguanine.", "relation": "1", "e1": "PURINETHOL", "e2": "TABLOID", "evs": ""}
{"sentence": "Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).", "relation": "0", "e1": "Tofranil", "e2": "clomipramine", "evs": ""}
{"sentence": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1> aminoglycosides </e1> , bacitracin, <e2> polymyxin B </e2> , colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.", "relation": "0", "e1": "aminoglycosides", "e2": "polymyxin B", "evs": ""}
{"sentence": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e2> thyroxine </e2> , triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.", "relation": "1", "e1": "Salicylate", "e2": "thyroxine", "evs": ""}
{"sentence": "ECG intervals (PR, QRS, and QT) were not affected by concurrent <e1> Mexitil </e1> and digoxin, diuretics, or <e2> propranolol </e2> .", "relation": "0", "e1": "Mexitil", "e2": "propranolol", "evs": ""}
{"sentence": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg <e1> methsuximide </e1> may increase the plasma concentrations of phenytoin and <e2> phenobarbital </e2> ).", "relation": "1", "e1": "methsuximide", "e2": "phenobarbital", "evs": ""}
{"sentence": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e1> metoclopramide </e1> , may diminish the effectiveness of <e2> MIRAPEX </e2> .", "relation": "1", "e1": "metoclopramide", "e2": "MIRAPEX", "evs": ""}
{"sentence": "Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).", "relation": "0", "e1": "furazolidone", "e2": "antihistamines", "evs": ""}
{"sentence": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, <e1> barbiturates </e1> , hypnotics, narcotic analgesics, sedatives, and <e2> tranquillisers </e2> .", "relation": "0", "e1": "barbiturates", "e2": "tranquillisers", "evs": ""}
{"sentence": "TRENTAL has been used concurrently with <e1> antihypertensive drugs </e1> , beta blockers, digitalis, diuretics, <e2> antidiabetic agents </e2> , and antiarrhythmics, without observed problems.", "relation": "0", "e1": "antihypertensive drugs", "e2": "antidiabetic agents", "evs": ""}
{"sentence": "Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.", "relation": "0", "e1": "desmethyldiazepam", "e2": "contraceptive", "evs": ""}
{"sentence": "When a single 100 mg dose of <e1> rimantadine HCl </e1> was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total <e2> rimantadine </e2> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).", "relation": "0", "e1": "rimantadine HCl", "e2": "rimantadine", "evs": ""}
{"sentence": "- Cisapride, pimozide: Other drugs such as <e1> cisapride </e1> or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2> macrolide antibacterials </e2> .", "relation": "1", "e1": "cisapride", "e2": "macrolide antibacterials", "evs": ""}
{"sentence": "<e1> MAO inhibitors </e1> and beta adrenergic blockers increase the effects of <e2> pseudoephedrine </e2> .", "relation": "1", "e1": "MAO inhibitors", "e2": "pseudoephedrine", "evs": ""}
{"sentence": "Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.", "relation": "1", "e1": "SUTENT", "e2": "ritonavir", "evs": ""}
{"sentence": "Other eye drops or medications such as acetylcholine chloride ( <e1> Miochol </e1> ) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of <e2> suprofen </e2> ophthalmic.", "relation": "1", "e1": "Miochol", "e2": "suprofen", "evs": ""}
